ImmuneRegen BioSciences, a development-stage biotechnology company and a wholly owned subsidiary of IR BioSciences Holdings, Inc. (IRBS.OB), announced the companyâ€™s submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to begin human clinical testing of HomsperaÂ® for the treatment of Idiopathic Pulmonary Fibrosis.
Currently afflicting 5 million people worldwide and killing 40,000 people annually, Idiopathic Pulmonary Fibrosis is a progressive interstitial lung disease characterized by scarring of lung tissue and over time prevents the lung from effectively transferring oxygen into the bloodstream. HomsperaÂ® is an adult stem cell active compound that has shown the ability to regenerate and strengthen the immune system as well as enhance wound healing. HomsperaÂ® has also been shown to affect a number of immunological and non-immunological cell types via its receptor-binding activity at the neurokinin-1 receptor (NK-1R).
ImmuneRegen BioSciences CEO, Michael K. Wilhelm, commented, â€œThis marks a major milestone in our efforts to explore the molecular mechanisms and capabilities of Homspera and its potential to treat a range of complications arising from damage to the immune system.â€ He added, â€œWe are encouraged by the results of pre-clinical studies of Homspera and look forward to taking our research to this next important level.â€